<span item_type="fundamental" item_id="6667c3fc8472da8c7ca1479a6f8c1a54" counter_id="ST/US/XOMAP" env="prod"></span><span item_type="announcement" item_id="581946250998583297" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 9.351 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.7.</p><p>EBIT: As of FY2025 Q3, the actual value is USD 1.971 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Income and revenue for the three and nine months ended September 30, 2025, were $9.4 million and $38.4 million, respectively, compared with $7.2 million and $19.8 million for the corresponding periods of 2024. The increase was primarily driven by increased income related to VABYSMO and OJEMDA.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income</strong>: XOMA Royalty reported net income of $14.1 million and $25.6 million for the three and nine months ended September 30, 2025, as compared to net losses of $17.2 million and $9.9 million in the corresponding periods of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li><li><strong>Operating Profit</strong>: Income (Loss) from operations was - $1.3 million for the three months ended September 30, 2025, compared to - $15.6 million for the same period in 2024. For the nine months ended September 30, 2025, it was $9.2 million compared to - $32.7 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li><li><strong>Operating Costs</strong>: R&amp;D expenses for the three and nine months ended September 30, 2025, were $69 thousand and $1.4 million, respectively, compared with $0.8 million and $2.0 million for the corresponding periods of 2024. G&amp;A expenses for the three and nine months ended September 30, 2025, were $9.7 million and $25.7 million, respectively, compared with $8.0 million and $27.5 million for the corresponding periods of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash provided by operating activities was $8.4 million for the nine months ended September 30, 2025, compared to - $10.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Cash Receipts</strong>: In the first nine months of 2025, XOMA Royalty received $43.9 million in cash from partners, including $30.3 million in royalties and $13.6 million in milestone payments and fees. In the third quarter, they received $14.3 million in cash from commercial sales.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li><li><strong>Gains on Acquisitions</strong>: In the third quarter of 2025, XOMA Royalty recorded gains on acquisitions of $17.9 million for HilleVax and $1.8 million for Turnstone.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>XOMA Royalty anticipates several clinical readouts over the coming months and quarters that, if positive, can meaningfully shape their business trajectory.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul>

XOMA Corp Pref Share 8.625 Perp 12/15/21 | 8-K: FY2025 Q3 Revenue: USD 9.351 M